May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Vision-Related Quality of Life in Subjects With Neovascular Age-Related Macular Degeneration (NV-AMD): A Comparison of Early and Established CNV Lesions
Author Affiliations & Notes
  • A. M. Pleil
    Pfizer Inc, New York, New York
  • R. Buggage
    Pfizer Inc, New York, New York
  • L. Chen
    Pfizer Inc, New York, New York
  • A. I. Barsdorf
    Pfizer Inc, New York, New York
  • G. Zlateva
    Pfizer Inc, New York, New York
  • Perspectives Study Group
    Pfizer Inc, New York, New York
  • Footnotes
    Commercial Relationships  A.M. Pleil, Pfizer, E; R. Buggage, Pfizer, E; L. Chen, Pfizer, E; A.I. Barsdorf, Pfizer, E; G. Zlateva, Pfizer, E.
  • Footnotes
    Support  Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 572. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Pleil, R. Buggage, L. Chen, A. I. Barsdorf, G. Zlateva, Perspectives Study Group; Vision-Related Quality of Life in Subjects With Neovascular Age-Related Macular Degeneration (NV-AMD): A Comparison of Early and Established CNV Lesions. Invest. Ophthalmol. Vis. Sci. 2008;49(13):572. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine relationships among baseline clinical and demographic characteristics and patient self-reported vision-related functioning and quality of life in NV-AMD subjects with early versus established CNV lesions.

Methods: : Data from 113 subjects who completed 30 weeks of follow-up in the PERSPECTIVES study, a multi-center, multi-national 102 week clinical trial for the treatment of NV-AMD, were included in this analysis. Assessments of visual function at baseline included distance visual acuity, near visual acuity, reading speed, and contrast sensitivity. Vision-related functioning and quality of life information was collected using the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) via a telephone interview administered by trained interviewers. CNV lesions were categorized as early or established by study investigators based on a combination of visual acuity, fundus photos, fluorescein and/or indocyanine green angiography.

Results: : Participants mean age was 74.0 years (±8.0). Sixty-seven (59%) patients were female, and 109 (97%) were white. No significant differences in demographic characteristics were found between subjects with early (n=35) or established (n=78) lesions. NV-AMD subjects with early lesions had significantly higher baseline assessments of reading speed (57.2 vs. 43.9; p=0.0064), mean distance visual acuity (68.29 vs. 57.0; p<.0001), contrast sensitivity (1.3 vs. 1.13; p=0.0127), and significantly better near visual acuity (0.46 vs. 0.66; p=0.0005) compared to patients with established lesions. Patients with early lesions had significantly higher NEI-VFQ mean scores for social functioning (85.98 vs. 74.08; p=.02), mental health (60.61 vs. 50.18; p=.048), and color vision (92.97 vs. 82.46; p=.02), and higher mean scores for composite (71.35 vs. 64.64), distance activities (67.05 vs. 60.60), role difficulties (65.15 vs. 58.46), and dependency (76.52 vs. 70.10) compared to patients with established lesions.

Conclusions: : Visual impairment and its impact on vision-related quality of life are evident in the early stages of NV-AMD and decline significantly as the disease progresses as defined by lesion state.

Clinical Trial: : www.clinicaltrials.gov NCT00327470

Keywords: visual acuity • quality of life • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×